» Articles » PMID: 26282231

CD147 Reprograms Fatty Acid Metabolism in Hepatocellular Carcinoma Cells Through Akt/mTOR/SREBP1c and P38/PPARα Pathways

Overview
Journal J Hepatol
Publisher Elsevier
Specialty Gastroenterology
Date 2015 Aug 19
PMID 26282231
Citations 119
Authors
Affiliations
Soon will be listed here.
Abstract

Background & Aims: CD147 is a transmembrane glycoprotein which is highly expressed in various human cancers including hepatocellular carcinoma (HCC). A drug Licartin developed with (131)Iodine-labeled antibody against CD147 has been approved by the Chinese Food and Drug Administration (FDA) and enters into clinical use for HCC treatment. Increasing lines of evidence indicate that CD147 is implicated in the metabolism of cancer cells, especially glycolysis. However, the molecular mechanism underlying the relationship between CD147 and aberrant tumor lipid metabolism remains elusive.

Methods: We systematically investigated the role of CD147 in the regulation of lipid metabolism, including de novo lipogenesis and fatty acid β-oxidation, in HCC cells and explored the underlying molecular mechanisms.

Results: Bioinformatic analysis and experimental evidence demonstrated that CD147 significantly contributed to the reprogramming of fatty acid metabolism in HCC cells mainly through two mechanisms. On one hand, CD147 upregulated the expression of sterol regulatory element binding protein 1c (SREBP1c) by activating the Akt/mTOR signaling pathway, which in turn directly activated the transcription of major lipogenic genes FASN and ACC1 to promote de novo lipogenesis. On the other hand, CD147 downregulated peroxisome proliferator-activated receptor alpha (PPARα) and its transcriptional target genes CPT1A and ACOX1 by activating the p38 MAPK signaling pathway to inhibit fatty acid β-oxidation. Moreover, in vitro and in vivo assays indicated that the CD147-mediated reprogramming of fatty acid metabolism played a critical role in the proliferation and metastasis of HCC cells.

Conclusion: Our findings demonstrate that CD147 is a critical regulator of fatty acid metabolism, which provides a strong line of evidence for this molecule to be used as a drug target in cancer treatment.

Citing Articles

Multi-omics analysis revealed the novel role of NQO1 in microenvironment, prognosis and immunotherapy of hepatocellular carcinoma.

Tang Y, Hu H, Chen S, Hao B, Xu X, Zhu H Sci Rep. 2025; 15(1):8591.

PMID: 40074806 PMC: 11903666. DOI: 10.1038/s41598-025-92700-7.


Profiling of RNA N6-Methyladenosine methylation reveals the critical role of m6A in betaine alleviating hepatic steatosis.

Wu Y, Yu J, Song H, Lu D, Li Z, Li X Sci Rep. 2025; 15(1):7298.

PMID: 40025137 PMC: 11873031. DOI: 10.1038/s41598-025-91573-0.


BRD1 deficiency affects SREBF1-related lipid metabolism through regulating H3K9ac/H3K9me3 transition to inhibit HCC progression.

Zhang M, Bai J, Yuan H, Duan X, Yu L, Li Y Cell Death Dis. 2025; 16(1):104.

PMID: 39962068 PMC: 11833140. DOI: 10.1038/s41419-025-07404-7.


The synergistic role of gut microbiota and RNA in metabolic diseases: mechanisms and therapeutic insights.

Huang Z, Yao Q, Ma S, Zhou J, Wang X, Meng Q Front Microbiol. 2025; 16:1504395.

PMID: 39944642 PMC: 11814227. DOI: 10.3389/fmicb.2025.1504395.


Altered Metabolites in Hepatocellular Carcinoma (HCC) Paving the Road for Metabolomics Signature and Biomarkers for Early Diagnosis of HCC.

Al-Amodi H, Kamel H Cureus. 2024; 16(10):e71968.

PMID: 39569240 PMC: 11576499. DOI: 10.7759/cureus.71968.